|
Market Closed -
Nasdaq
04:00:00 2026-09-11 pm EDT
|
5-day change | 1st Jan Change | ||
| 143.97 USD | +5.38% |
|
-1.09% | +388.20% |
| Sep. 11 | Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating | MT |
| Sep. 09 | Moderna Set for 3 Near-Term INT Data Readouts, UBS Says | MT |
| Market Cap | 57.48B 49.52B 46.89B 42.5B 79.74B 5,491B 80.14B 557B 214B 2,794B 216B 211B 8,828B | P/E 2026 * |
-17.2x | P/E 2027 * | -30.1x |
|---|---|---|---|---|---|
| Enterprise Value | 53.83B 46.38B 43.91B 39.8B 74.67B 5,142B 75.05B 522B 201B 2,616B 202B 198B 8,267B | EV / Sales 2026 * |
25.6x | EV / Sales 2027 * | 22.7x |
| Free-Float |
92.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
Xetra
| 0QF | Delayed | |
|
Tradegate
| 0QF | Real-time | |
|
Boerse Muenchen
| 0QF | Real-time | |
|
CBOE
| Real-time | ||
|
CBOE
| 0A45 | Real-time | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed | |
|
London S.E.
| 0A45 | Delayed | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
Lima
| MRNAUS | End-of-day quote | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript : Moderna, Inc.
| 1 day | +5.38% | ||
| 1 week | -1.09% | ||
| Current month | +2.59% | ||
| 1 month | +126.12% | ||
| 3 months | +188.46% | ||
| 6 months | +169.66% | ||
| Current year | +388.20% |
| 1 week | 130.38 |  | 149.73 |
| 1 month | 60.82 | | 176.66 |
| Current year | 29.81 | | 176.66 |
| 1 year | 22.28 | | 176.66 |
| 3 years | 22.28 | | 176.66 |
| 5 years | 22.28 | | 458.5 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 2011-02-28 |
James Mock
DFI | Director of Finance/CFO | 49 | 2022-09-05 |
Stephen Hoge
PSD | President | 50 | 2024-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 2012-01-31 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 2011-02-28 |
Francois Nader
BRD | Director/Board Member | 69 | 2019-12-10 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/4/26 | Exercice | General Counsel | 29,298 | 0.0073% | ||
| 9/4/26 | Exercice | Chief Financial Officer | 29,298 | 0.0073% | ||
| 9/1/26 | Exercice | General Counsel | 15,793 | 0.0040% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.38% | -1.09% | +512.38% | +36.80% | 57.48B | |
| -1.48% | -5.59% | +39.55% | -6.16% | 78.04B | |
| -1.42% | -4.24% | -19.59% | -38.20% | 57.4B | |
| -0.56% | -2.21% | -11.34% | +27.29% | 48.81B | |
| +1.93% | -2.37% | -0.87% | +149.45% | 45.5B | |
| +0.80% | -1.67% | +49.90% | -15.98% | 32.08B | |
| -1.47% | -4.17% | +46.17% | +89.12% | 24.62B | |
| -0.85% | -8.64% | -4.39% | +161.31% | 20.77B | |
| -0.09% | -3.61% | +62.49% | +98.37% | 15.75B | |
| -0.08% | -3.21% | +41.46% | +153.73% | 14.16B | |
| Average | +0.22% | -3.81% | +71.58% | +65.57% | 39.46B | |
| Weighted average by Cap. | +0.36% | -3.69% | +88.79% | +41.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.81B 1.71B 1.55B 2.91B 201B 2.93B 20.36B 7.83B 102B 7.89B 7.72B 323B | 2.44B 2.1B 1.99B 1.8B 3.38B 233B 3.4B 23.62B 9.08B 118B 9.16B 8.96B 374B |
| Net income | -3.31B -2.85B -2.7B -2.45B -4.6B -316B -4.62B -32.1B -12.34B -161B -12.44B -12.17B -509B | -1.94B -1.68B -1.59B -1.44B -2.7B -186B -2.71B -18.84B -7.25B -94.51B -7.3B -7.14B -299B |
| Net Debt | -3.65B -3.15B -2.98B -2.7B -5.07B -349B -5.09B -35.39B -13.61B -178B -13.72B -13.42B -561B | -2.17B -1.87B -1.77B -1.6B -3.01B -207B -3.03B -21.03B -8.09B -105B -8.15B -7.97B -333B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | $143.97 | +5.38% | 15,409,297 |
| 26-09-10 | $136.62 | +0.74% | 7,873,511 |
| 26-09-09 | $135.61 | -3.36% | 8,650,474 |
| 26-09-08 | $140.33 | -3.59% | 10,308,621 |
| 26-09-04 | $145.55 | -2.23% | 14,966,547 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
